Fundraising Fox
AIMA
Techstars '24Vancouver, CA · Founded 2019 · 2 employees on LinkedIn · 2 known investors
Find your way into AIMA
Sign up to see every warm intro you have to AIMA
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AIMA team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OVY makes water-based suppositories for managing severe pelvic pain associated with conditions like endometriosis and uterine fibroids during menstruation. The product is designed for patients with pelvic floor muscle tension and aims to provide rapid pain relief without disrupting vaginal health.
Also known as OVY · OVY Relief
Founders & leadership
AIMA was founded in 2019 by Lanna Last and Dr. Mali Meibod.
Investors · 2
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · open dataset · 5k.vc investor directory · Not right? Tell us
Company profile
researched Sep 2026AIMA is a women's health company focused on non-opioid treatments for pelvic and menstrual pain. Its commercial line, OVY Relief, consists of vaginal suppositories formulated with cannabinoids and related compounds — CBD, CBDA, CBG and PEA (palmitoylethanolamide) — alongside daily oral capsules and a combined relief kit. The company states that relief is typically felt within 30–45 minutes of using the suppositories and can last up to eight hours, and that formulations are hypoallergenic, THC-free in the sense of containing less than 0.3% THC, and made with natural ingredients.
Products are described as water-based, intended not to disrupt the vaginal microenvironment or alter its pH, and usable by people with significant pelvic floor muscle tension, including those managing pain associated with endometriosis. Beyond the marketed products, the company says it is developing a pipeline of patent-protected, clinically assessed therapies for pelvic pain, and frames its positioning around science-driven innovation, patient-centred solutions, equitable access to care and a women-led mission.
Business model
AIMA sells consumer health products directly through its own e-commerce site, offering single packs, multi-packs, a relief kit and a daily capsule product, with a subscription option that provides a 20% discount and priority delivery. It also states that it partners with healthcare systems and works with practitioners.
Direct-to-consumer product sales at listed prices (suppositories 5ct at $35.99, 10ct two-pack at $69.69, the OVY Relief Kit at $105.99, and daily capsules 30ct at $69.66), plus a recurring subscription plan at a 20% discount.
Traction
The company states its products are trusted by more than 700 practitioners. A third-party review aggregator lists a 4.6 rating based on user reviews of my-aima.com.
Latest developments
AIMA describes commercialized products in the U.S., expansion into Australia, partnerships with healthcare systems, and a developing pipeline of patent-protected, clinically assessed pelvic pain therapies.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Positioned in the women's health and pelvic pain segment as a non-opioid, plant-based alternative, citing use by more than 700 practitioners and clinical backing.
Differentiators cited include a water-based formulation that does not disrupt the vaginal microenvironment or pH, high-dose CBD and CBG content, rapid onset with up to eight hours of duration, patent-protected pipeline candidates, and a non-opioid approach to pelvic pain.
Technology
Cannabinoid-based topical/intravaginal formulations combining CBD, CBDA, CBG and PEA in water-based suppositories, plus oral daily capsules. The company describes the products as clinically tested, containing less than 0.3% THC, and designed not to alter vaginal pH, and says its pipeline therapies are patent-protected.
Go-to-market
The company markets directly to consumers online using promotional discount codes and subscription offers, while also citing endorsement and use by practitioners and partnerships with healthcare systems.
Women and menstruators experiencing pelvic and menstrual pain, including those with endometriosis and pelvic floor muscle tension, as well as clinicians who recommend such products.
Geography
Products are commercialized in the United States, with stated expansion into Australia.
Risks & controversies
Third-party review commentary notes the products' cost as a limitation for regular use, delivery times of 8–11 days, and the absence of an extra-strength dose option.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Related companies · 6
Companies working in the same space as AIMA.
▸Research sources · 8
primary sources listed
- AIMAmy-aima.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does AIMA do?
- AIMA is a women's health company selling OVY Relief CBD/CBG vaginal suppositories and capsules for pelvic and menstrual pain.
- Who founded AIMA?
- AIMA was founded by Lanna Last, Dr. Mali Meibod in 2019.
- Who are AIMA's investors?
- AIMA's investors include SOSV, Techstars.
- Where is AIMA headquartered?
- AIMA is headquartered in Vancouver, CA.